Amgen Inc. (NASDAQ:AMGN)‘s stock had its “outperform” rating restated by Cowen and Company in a note issued to investors on Saturday. They currently have a $209.00 price objective on the medical research company’s stock. Cowen and Company’s price target indicates a potential upside of 15.98% from the stock’s previous close.

A number of other equities research analysts have also weighed in on the stock. BMO Capital Markets restated a “buy” rating and issued a $199.00 price objective on shares of Amgen in a report on Friday. Jefferies Group LLC restated a “buy” rating and issued a $195.00 price objective on shares of Amgen in a report on Monday, July 17th. Credit Suisse Group AG set a $177.00 price objective on shares of Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $189.00 price objective on shares of Amgen in a report on Friday, July 14th. Finally, Morgan Stanley restated an “overweight” rating on shares of Amgen in a report on Monday, July 10th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have given a buy rating and three have issued a strong buy rating to the company. Amgen currently has an average rating of “Buy” and a consensus target price of $185.21.

Amgen (NASDAQ:AMGN) traded up 0.50% during trading on Friday, reaching $180.21. 2,674,714 shares of the company’s stock traded hands. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The company has a market cap of $132.53 billion, a PE ratio of 17.12 and a beta of 1.36. The company has a 50 day moving average price of $169.47 and a 200-day moving average price of $165.39.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the business earned $2.90 EPS. The company’s revenue was down 1.1% on a year-over-year basis. On average, equities research analysts forecast that Amgen will post $12.47 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/22/amgen-inc-nasdaqamgn-rating-reiterated-by-cowen-and-company.html.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of AMGN. Gilbert & Cook Inc. purchased a new stake in Amgen during the second quarter worth approximately $230,000. Duncker Streett & Co. Inc. raised its stake in Amgen by 8.3% in the second quarter. Duncker Streett & Co. Inc. now owns 5,580 shares of the medical research company’s stock worth $961,000 after buying an additional 430 shares during the period. Huntington National Bank raised its stake in Amgen by 1.2% in the second quarter. Huntington National Bank now owns 251,054 shares of the medical research company’s stock worth $43,239,000 after buying an additional 3,090 shares during the period. Bridges Investment Counsel Inc. raised its stake in Amgen by 82.4% in the second quarter. Bridges Investment Counsel Inc. now owns 25,869 shares of the medical research company’s stock worth $4,455,000 after buying an additional 11,688 shares during the period. Finally, Private Bank & Trust Co. raised its stake in Amgen by 19.2% in the second quarter. Private Bank & Trust Co. now owns 4,190 shares of the medical research company’s stock worth $721,000 after buying an additional 676 shares during the period. 78.80% of the stock is owned by institutional investors.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.